Breaking News

Allergan Buys Chase Pharma

Expands CNS pipeline with Phase III-ready AD candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan has completed the acquisition of Chase Pharmaceuticals Corp., a clinical-stage biopharma company developing treatments for neurodegenerative disorders including Alzheimer’s disease (AD). Allergan paid $125 million upfront and additional potential regulatory and sales milestone payments related to Chase’s lead compound, CPC-201, and certain backup compounds. CPC-­201 is a combination of the most commonly prescribed acetylcholinesterase inhibitor (AChEI), donepezil, and the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters